Brainstorm Cell Therapeutics Inc Asset Resilience Ratio

Latest as of December 2023: 0.00%

Brainstorm Cell Therapeutics Inc asset resilience ratio. Brainstorm Cell Therapeutics Inc (BCLI) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BCLI days of operational coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$0.00

Cash + Short-term Investments

Total Assets

$4.21 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Brainstorm Cell Therapeutics Inc (2011–2023)

Asset resilience ratio of Brainstorm Cell Therapeutics Inc from 2011 to 2023. This chart shows how Brainstorm Cell Therapeutics Inc's Asset Resilience Ratio has changed over time. Read BCLI liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Brainstorm Cell Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BCLI total asset value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$0.00	0%
Total Liquid Assets	$0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Brainstorm Cell Therapeutics Inc maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Brainstorm Cell Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Brainstorm Cell Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
CSL Ltd AU:CSL	Biotechnology	0.41%
Genmab A/S CO:GMAB	Biotechnology	23.50%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Xizang Haisco Pharmaceutical Group Co Ltd SHE:002653	Biotechnology	1.69%
Abivax SA American Depositary Shares NASDAQ:ABVX	Biotechnology	4.91%
Bachem Holding AG SW:BANB	Biotechnology	0.00%
Viking Therapeutics Inc NASDAQ:VKTX	Biotechnology	72.03%
SOLENO THERAPEUT. DL-001 F:6XC	Biotechnology	41.74%

Brainstorm Cell Therapeutics Inc Asset Resilience Ratio by Year (2011–2023)

Brainstorm Cell Therapeutics Inc asset resilience ratio by year from 2011 to 2023. The table below shows the annual Asset Resilience Ratio data for Brainstorm Cell Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	0.00%	$0.00	$4.21 Million	--
2022-12-31	26.16%	$2.21 Million	$8.45 Million	+15.10pp
2021-12-31	11.06%	$3.24 Million	$29.28 Million	+3.05pp
2020-12-31	8.01%	$4.11 Million	$51.26 Million	+7.51pp
2019-12-31	0.51%	$33.00K	$6.53 Million	-54.02pp
2018-12-31	54.52%	$6.12 Million	$11.23 Million	+8.36pp
2017-12-31	46.16%	$5.27 Million	$11.42 Million	-41.55pp
2016-12-31	87.71%	$9.44 Million	$10.77 Million	-3.20pp
2015-12-31	90.91%	$15.53 Million	$17.08 Million	+47.62pp
2014-12-31	43.29%	$4.29 Million	$9.91 Million	--
2013-12-31	0.00%	$0.00	$4.73 Million	--
2012-12-31	52.15%	$2.77 Million	$5.31 Million	--
2011-12-31	0.00%	$0.00	$2.74 Million	--

pp = percentage points

About Brainstorm Cell Therapeutics Inc

NASDAQ:BCLI USA Biotechnology

Market Cap

$11.73 Million

Market Cap Rank

#26539 Global

#5547 in USA

Share Price

$1.06

Change (1 day)

-1.60%

52-Week Range

$0.48 - $1.41

All Time High

$265.95